Clinical efficacy of Shaomazhijing granules in the treatment of Tourette's syndrome: a randomized controlled trial.

IF 2.7 3区 生物学
Yan-Zhen Wang, Jiang Yang, Xin-Min Han
{"title":"Clinical efficacy of Shaomazhijing granules in the treatment of Tourette's syndrome: a randomized controlled trial.","authors":"Yan-Zhen Wang, Jiang Yang, Xin-Min Han","doi":"10.1186/s41065-025-00462-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>We designed this study to verify the clinical efficacy and safety of Shaomazhijing granules, a Chinese patent medicine, in the treatment of Tourette's syndrome (TS) with liver-yang hyperactivity, liver wind, and phlegm-fire disturbance.</p><p><strong>Methods: </strong>We enrolled a total of 603 children and adolescents aged 5-18 years with TS in this randomized, double-blinded, multicenter study. We randomly assigned participants to a Shaomazhijing granules group, a Tiapride group, or a placebo group in a ratio of approximately 3:1:1, respectively. We evaluated the treatment results using the traditional Chinese medicine (TCM) syndrome quantitative classification scale and also compared the incidence of adverse events among the three groups.</p><p><strong>Results: </strong>The TCM syndrome of all patients improved over time. At week eight of TCM treatment, the overall syndrome score, primary symptoms (muscle tics), and secondary symptoms (emotional and psychological) of patients in the Shaomazhijing granules and tiapride groups showed significant improvements when compared to that of patients in the placebo group. Compared with the tiapride group, the Shaomazhijing granules group showed better improvement in the secondary symptoms (P < 0.05). While the clinical efficacy for primary symptoms of patients in the Shaomazhijing granules was similar (P = 0.969) with that of patients in tiapride groups. The TCM syndrome clinical control rate and the clinically excellent effectiveness rate of the Shaomazhijing granules group (3.45% and 44.51%) and tiapride group (2.86% and 26.67%) were higher than that of the patients in placebo group (1.04% and 12.50%, P < 0.001). Patients in placebo group (11.2%) and Shaomazhijing granules group (13.8%) had significantly lower overall adverse event rates in comparison with those in tiapride group (26.8%, P = 0.002).</p><p><strong>Conclusion: </strong>The clinical efficacy of Shaomazhijing granules is comparable to tiapride in reducing reducing the primary symptoms (muscle tics) of TS. Besides, it showed better efficacy in improving secondary (emotional and psychological) symptoms. Its safety profile is better than tiapride. Based on these results, Shaomazhijing granules can be considered a safe and effective treatment for patients with TS.</p>","PeriodicalId":12862,"journal":{"name":"Hereditas","volume":"162 1","pages":"90"},"PeriodicalIF":2.7000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125844/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hereditas","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s41065-025-00462-z","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: We designed this study to verify the clinical efficacy and safety of Shaomazhijing granules, a Chinese patent medicine, in the treatment of Tourette's syndrome (TS) with liver-yang hyperactivity, liver wind, and phlegm-fire disturbance.

Methods: We enrolled a total of 603 children and adolescents aged 5-18 years with TS in this randomized, double-blinded, multicenter study. We randomly assigned participants to a Shaomazhijing granules group, a Tiapride group, or a placebo group in a ratio of approximately 3:1:1, respectively. We evaluated the treatment results using the traditional Chinese medicine (TCM) syndrome quantitative classification scale and also compared the incidence of adverse events among the three groups.

Results: The TCM syndrome of all patients improved over time. At week eight of TCM treatment, the overall syndrome score, primary symptoms (muscle tics), and secondary symptoms (emotional and psychological) of patients in the Shaomazhijing granules and tiapride groups showed significant improvements when compared to that of patients in the placebo group. Compared with the tiapride group, the Shaomazhijing granules group showed better improvement in the secondary symptoms (P < 0.05). While the clinical efficacy for primary symptoms of patients in the Shaomazhijing granules was similar (P = 0.969) with that of patients in tiapride groups. The TCM syndrome clinical control rate and the clinically excellent effectiveness rate of the Shaomazhijing granules group (3.45% and 44.51%) and tiapride group (2.86% and 26.67%) were higher than that of the patients in placebo group (1.04% and 12.50%, P < 0.001). Patients in placebo group (11.2%) and Shaomazhijing granules group (13.8%) had significantly lower overall adverse event rates in comparison with those in tiapride group (26.8%, P = 0.002).

Conclusion: The clinical efficacy of Shaomazhijing granules is comparable to tiapride in reducing reducing the primary symptoms (muscle tics) of TS. Besides, it showed better efficacy in improving secondary (emotional and psychological) symptoms. Its safety profile is better than tiapride. Based on these results, Shaomazhijing granules can be considered a safe and effective treatment for patients with TS.

少麻直精颗粒治疗抽动秽语综合征的临床疗效:随机对照试验。
目的:验证中成药少麻直精颗粒治疗肝阳亢、肝风、痰火紊乱型抽动秽气综合征(TS)的临床疗效和安全性。方法:在这项随机、双盲、多中心研究中,我们共招募了603名5-18岁的TS儿童和青少年。我们将参与者随机分配到少麻芝净颗粒组、噻必利组和安慰剂组,比例分别约为3:1:1。采用中医证候定量分级量表对治疗效果进行评价,并比较三组患者不良事件发生率。结果:所有患者中医证候均随时间改善。在中医治疗的第8周,与安慰剂组相比,少麻栀静颗粒组和噻必利组患者的总证候评分、原发性症状(肌肉抽搐)和继发症状(情绪和心理)均有显著改善。与噻必利组比较,少麻子精颗粒组对TS继发症状的改善效果更好(P)。结论:少麻子精颗粒在减轻TS原发性症状(肌肉抽搐)方面的临床疗效与噻必利相当,对TS继发症状(情绪、心理)的改善效果更好。其安全性优于噻必利。综上所述,少麻芝精颗粒治疗TS是一种安全有效的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hereditas
Hereditas Biochemistry, Genetics and Molecular Biology-Genetics
CiteScore
3.80
自引率
3.70%
发文量
0
期刊介绍: For almost a century, Hereditas has published original cutting-edge research and reviews. As the Official journal of the Mendelian Society of Lund, the journal welcomes research from across all areas of genetics and genomics. Topics of interest include human and medical genetics, animal and plant genetics, microbial genetics, agriculture and bioinformatics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信